Market Intelligence, Clinical Progress, and High-Purity Reagents for Integrated Stress Response (ISR) Modulator Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EIF2AK1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EIF2AK1 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for kinase assays. |
View EIF2AK1 Products |
| Gene Delivery | EIF2AK1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cellular stress assays. |
View EIF2AK1 Products |
| Benchmark Ab | Anti-EIF2AK1 Recombinant Antibody Recombinant positive control for western blot and ELISA validation. |
View EIF2AK1 Products |
| Validator | EIF2AK1 siRNA Set For knockdown verification and pathway specificity control. |
View EIF2AK1 Products |
| Related Target A | EIF2S1 Direct downstream substrate of EIF2AK1; essential for in vitro phosphorylation assays. |
View EIF2S1 Products |
| Related Target B | EIF2AK3 (PERK) Family member used for off-target selectivity and counter-screening panels. |
View EIF2AK3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Activity & Autophosphorylation | High-purity active recombinant EIF2AK1 kinase domain with verified sequence identity. |
| Family-wide Selectivity Screening | Homolog panel proteins (PERK, PKR, GCN2) strictly verified by mass spectrometry to eliminate cross-reactivity. |
| Lack of Controls | Recombinant Benchmark Antibodies included for assay standardization. |
| False Positives in Cellular Assays | Sequence-specific siRNA sets included for target-specific knockdown validation. |
Live EIF2AK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EIF2AK1 (also known as HRI, Heme-Regulated Inhibitor) therapeutics is intensifying, with major players shifting focus from traditional oncology models to targeted Integrated Stress Response (ISR) modulation. As first-generation small molecule inhibitors enter preclinical and early clinical validation, the next wave of R&D is targeting highly selective allosteric sites to bypass systemic toxicity associated with pan-eIF2a kinase inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Denali Therapeutics, AbbVie, Roche | Neurodegenerative Diseases, Solid Tumors | Selectivity Assay (Need EIF2AK1 vs. EIF2AK3/PERK recombinant proteins) |
| Small Molecule Activators | Disclosed Biotech Consortia | Hemoglobinopathies (Sickle Cell, Beta-Thalassemia) | Substrate Phosphorylation (Need high-purity EIF2S1 substrate) |
| RNA Therapeutics | Academic Spin-offs | Metabolic Disorders, Stress-Induced Pathology | Target Knockdown Validation (Need validated siRNA and Lentiviral vectors) |